Positive Phase 2 Results for Edasalonexant in DMD Support Phase 3 Study

Catabasis’s small molecule NF-kB inhibitor showed promise in phase 2, and the phase 3 PolarisDMD study (NCT03703882) of edasalonexant is fully enrolled and expected to read out in late 2020.

Source link

Related posts

What's happening in Neurology(R) Neuroimmunology & Neuroinflammation


Identifying Intracranial Hypertension in Children: Added Challenges


Author response: Quality of life predicts outcome of deep brain stimulation in early Parkinson disease


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy